Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.53 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.53 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1171418 | 0.94 | LMNA (0.56) | TPSAB1TPSD1TPSG1ALDH1A1L3MBTL1 | |
| SCHEMBL10081124 | 0.90 | LMNA (0.63) | TPSAB1TPSD1TPSG1ALDH1A1L3MBTL1 | |
| SCHEMBL15271773 | 0.88 | LMNA (0.54) | TPSAB1TPSD1TPSG1ALDH1A1L3MBTL1 | |
| SCHEMBL5408406 | 0.85 | HTT (0.58) | TPSAB1TPSD1TPSG1ALDH1A1L3MBTL1 | |
| SCHEMBL6900428 | 0.84 | PPID (0.60) | TPSAB1TPSD1TPSG1ALDH1A1L3MBTL1 | |
| SCHEMBL2184736 | 0.84 | L3MBTL1 (0.53) | TPSAB1TPSD1TPSG1ALDH1A1L3MBTL1 | |
| SCHEMBL23748823 | 0.84 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1MAPK1LMNAMEN1 | |
| SCHEMBL2224146 | 0.83 | L3MBTL1 (0.54) | TPSAB1TPSD1TPSG1ALDH1A1L3MBTL1 | |
| SCHEMBL3861269 | 0.83 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1MAPK1LMNASMN1; SMN2 | |
| SCHEMBL25243105 | 0.82 | HTT (0.68) | TPSAB1TPSD1TPSG1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4566608-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-4440702-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4445900-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12187753-B2 | Therapeutics compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4445900-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4440702-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240132527-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2024-04-25 | — | — | US | disclosed |
| US-11787825-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230203069-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023102239-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| EP-2825528-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| WO-2013135648-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-09-19 | — | — | WO | disclosed |
| US-20130244958-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN-LA ROCHE INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20090209585-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCTION OF THE DERIVATIVES, AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090209585-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCTION OF THE DERIVATIVES, AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090209585-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCTION OF THE DERIVATIVES, AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-20 | — | — | US | disclosed |
| EP-2039681-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCTION OF THE DERIVATIVES, AND USE OF THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
| EP-2039681-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCTION OF THE DERIVATIVES, AND USE OF THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
| US-7169803-B2 | N-substituted prodrugs of fluorooxindoles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-20050203089-A1 | N-substituted prodrugs of fluorooxindoles | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203089-A1 | N-substituted prodrugs of fluorooxindoles | KCNA5, KCNQ5, KCNQ2 | TPSAB1 2469/4885TPSD1 1061/4885TPSG1 2699/4885 |
| US-20090209585-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCTION OF THE DERIVATIVES, AND USE OF THE SAME | SQLE, FDFT1, PTGIS | TPSAB1 398/4885TPSD1 105/4885TPSG1 1103/4885 |
| US-20130244958-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | CCNY, ARG2, RPS4Y1 | TPSAB1 3425/4885TPSD1 2159/4885TPSG1 4042/4885 |
| US-11787825-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | TPSAB1 4396/4885TPSD1 4556/4885TPSG1 2179/4885 |
| US-12187753-B2 | Therapeutics compounds for HIV virus infection | CD4, HAVCR2, MAVS | TPSAB1 4145/4885TPSD1 4538/4885TPSG1 1765/4885 |
| US-20230203069-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | HAVCR2, MAVS, CD4 | TPSAB1 4396/4885TPSD1 4556/4885TPSG1 2179/4885 |
| US-20240132527-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | CD4, HAVCR2, MAVS | TPSAB1 4145/4885TPSD1 4538/4885TPSG1 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.